Diplomat to sell Tesaro’s cancer drug

Diplomat Pharmacy will distribute Zejula (niraparib) for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Zejula has been approved by US Food and Drug Administration (FDA) as a once-daily oral maintenance treatment for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum based chemotherapy.

Zejula is manufactured by Tesaro and will be launched in United States in late April, Diplomat said in its press release.

This drug is the first poly ADP-ribose polymerase inhibitor to be approved by the FDA that does not require BRCA mutation or other biomarker testing, the company noted.